 Preclinical data suggest that TMPRSS2-ERG gene fusions, present in about 50% of prostate cancers, may be a surrogate for DNA repair status and therefore a biomarker for DNA-damaging agents.     ///    TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair..     ///    "To test this hypothesis, we examined whether TMPRSS2-ERG status was associated with biochemical failure after clinical induction of DNA damage following image-guided radiotherapy (IGRT). "    ///    The potential role of TMPRSS2-ERG status as a prognostic factor for biochemical relapse-free rate (bRFR.     ///    TMPRSS2-ERG is therefore unlikely to be a predictive factor for IGRT response..     ///    "In two similarly treated IGRT cohorts, TMPRSS2-ERG status was not prognostic for bRFR, in disagreement with the hypothesis that these prostate cancers have DNA repair defects that render them clinically more radiosensitive. "    ///    "In both cohorts, TMPRSS2-ERG status was not associated with bRFR on univariate or multivariate analysis. "